Speakers 2014
AGARWAL Kosh
UK
-
Treatment of HCV cirrhosis and transplanted patients
Presentation
-
AGHEMO Alessio
Italy
-
The long term impact of treatment on the outcome of liver disease?
Presentation
-
ANTY Rodolphe
France
-
Traitement des patients rechuteurs et non-répondeurs (French speaking luncheon)
Presentation
-
-
State of the art lecture and Award (chairman)
-
Genotype 4
-
Advantages of 2nd generation triple therapy
-
How to optimize treatment in G4 patients? (chairman)
Presentation
-
-
Staging of fibrosis: liver biopsy or indirect markers?
Presentation
-
BELHADJ BRIK Najet
Tunisia
-
Interféron ou analogue ? (French speaking luncheon)
Presentation
-
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon) (chairman)
Presentation
-
BENHAMOU Yves
France
-
Treat now
-
Future therapeutic strategies with direct acting antivirals (chairman)
Presentation
-
-
Triple therapy with telaprevir or boceprevir: management of side effects
Presentation
-
-
Optimal therapy of HBeAg-negative chronic hepatitis B (chairman)
Presentation
-
-
Personalized treatment with boceprevir
Presentation
-
BOYER Nathalie
France
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon) (chairman)
Presentation
-
-
Traitement des patients rechuteurs et non-répondeurs (French speaking luncheon) (chairman)
Presentation
-
BRUNETTO Maurizia
Italy
-
Clinical applications of HBsAg quantification (chairman)
-
HBsAg quantitation : useful for staging the liver disease?
Presentation
-
-
Patients with cirrhosis
Presentation
-
-
Why do I treat my patient with a NUC?
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy?
Presentation
-
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon) (chairman)
Presentation
-
CARDOSO Ana Carolina
Brazil
-
Staging of fibrosis: liver biopsy or indirect markers?
Presentation
-
-
Are non-invasive markers of fibrosis reliable?
Presentation
-
-
Clinical applications of HBsAg quantification (chairman)
-
The control of HBV related liver disease (chairman)
Presentation
-
-
First line therapy: interferon or analogues? (chairman)
-
Impact of HBV therapy on the incidence of hepatocellular carcinoma
Presentation
-
-
Regression of fibrosis. Is cirrhosis reversible?
-
How to optimize treatment in G1 naive patients? (chairman)
Presentation
-
-
Staging of fibrosis: liver biopsy or indirect markers? (chairman)
Presentation
-
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon)
Presentation
-
DELFRAISSY Jean-François
France
-
ANRS: perspectives for basic research in viral hepatitis
Presentation
-
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon) (chairman)
Presentation
-
DI MARTINO Vincent
France
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon)
Presentation
-
-
HIV-HCV coinfections (chairman)
-
HIV co-infected patients
Presentation
-
-
Special populations (chairman)
Presentation
-
-
Triple therapy with telaprevir or boceprevir: management of side effects (chairman)
-
When to stop NUCs?
Presentation
-
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy? (chairman)
Presentation
-
FLISIAK Robert
Poland
-
Controversy: F1/F2 patients: treat or wait? (chairman)
-
Triple therapy with telaprevir or boceprevir: management of side effects
Presentation
-
-
Personalized treatment with telaprevir
-
How to optimize current therapy of non G1 patients (chairman)
Presentation
-
-
The long term impact of treatment on the outcome of liver disease? (chairman)
-
Optimal therapy of HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
-
Genotype 2
Presentation
-
-
Resistance to DAAs: is this a real issue?
Presentation
-
-
Traitement des patients rechuteurs et non-répondeurs (French speaking luncheon) (chairman)
Presentation
-
HORBAN Andrzej
Poland
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy? (chairman)
Presentation
-
-
How to optimize treatment in G1 naive patients?
Presentation
-
-
How to optimize current therapy of G1 patients (chairman)
-
HIV-HCV coinfections (chairman)
Presentation
-
-
Optimal therapy of HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
-
Why do I treat my patient with pegylated IFN?
Presentation
-
-
Resistance to DAAs: is this a real issue?
Presentation
-
-
Why do I treat my patient with a NUC?
Presentation
-
-
First line therapy: interferon or analogues?
-
New therapeutic perspectives (chairman)
Presentation
-
-
Staging of fibrosis: liver biopsy or indirect markers? (chairman)
-
Special populations (chairman)
Presentation
-
LEROY Vincent
France
-
How to optimize treatment in G4 patients?
Presentation
-
-
Future therapeutic strategies with direct acting antivirals (chairman)
Presentation
-
-
New interferons and immunomodulators
Presentation
-
LIM Seng Gee
Singapore
-
Optimal therapy of HBeAg-negative chronic hepatitis B (chairman)
Presentation
-
MANNS Michael
Germany
-
How to optimize current therapy of non G1 patients (chairman)
Presentation
-
-
Introduction: Treatment of hepatitis C: soon the end of the road ?
-
State of the art lecture and Award (chairman)
-
Conclusion
-
Introduction: HBV: Who, when and how to treat? (chairman)
-
Conclusion: tomorrow and after tomorrow?
Presentation
-
-
HBsAg quantitation : useful for the indication and follow-up of therapy ?
Presentation
-
MATHURIN Philippe
France
-
Resistance to DAAs: is this a real issue? (chairman)
Presentation
-
-
New therapeutic strategies (chairman)
Presentation
-
-
How to optimize current therapy of G1 patients (chairman)
Presentation
-
OULD GOUGAM Rachid
Algeria
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon)
Presentation
-
-
Clinical applications of HBsAg quantification
Presentation
-
PAIS Raluca
France
-
Traitement des patients rechuteurs et non-répondeurs (French speaking luncheon)
Presentation
-
-
Why do I treat my patient with pegylated IFN?
Presentation
-
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy?
Presentation
-
-
Triple therapy with telaprevir or boceprevir: management of side effects (chairman)
Presentation
-
PETERSEN Jorg
Germany
-
First line therapy: interferon or analogues?
Presentation
-
-
First line therapy: interferon or analogues? (chairman)
Presentation
-
-
Genotype 3
Presentation
-
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon)
Presentation
-
RATZIU Vlad
France
-
How to optimize treatment in G1 naive patients? (chairman)
Presentation
-
-
New therapeutic perspectives (chairman)
Presentation
-
ROCKSTROH Juergen
Germany
-
HIV-HCV coinfections
Presentation
-
SALMON Dominique
France
-
HIV-HCV coinfections
Presentation
-
-
Treatment of HCV cirrhosis and transplanted patients (chairman)
-
Transplant patients
Presentation
-
SAYEGH Raymond
Lebanon
-
Interféron ou analogue ? (French speaking luncheon)
Presentation
-
-
Controversy: F1/F2 patients: treat or wait? (chairman)
Presentation
-
-
Protease, polymerase and NS5A inhibitors: what will be the wining combination?
-
Resistance to DAAs: is this a real issue? (chairman)
Presentation
-
SERFATY Lawrence
France
-
Is there still a role for PEG IFN+RBV therapy?
Presentation
-
-
Still wait
Presentation
-
SOBESKY Rodolphe
France
-
Treatment of HCV cirrhosis and transplanted patients
Presentation
-
SOGNI Philippe
France
-
Interféron ou analogue ? (French speaking luncheon) (chairman)
Presentation
-
-
Do we still need ribavirin?
-
Future therapeutic strategies with direct acting antivirals
Presentation
-
TRAN Albert
France
-
Clinical applications of HBsAg quantification
Presentation
-
-
Milestones in viral hepatitis
Presentation
-
URBANEK Petr
Czech Republic
-
How to optimize treatment in G1 naive patients?
Presentation
-
VALLA Dominique
France
-
Treatment of HCV cirrhosis and transplanted patients (chairman)
Presentation
-
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon) (chairman)
Presentation
-
-
How to optimize treatment in G4 patients?
Presentation
-
WEILAND Ola
Sweden
-
Future therapeutic strategies with direct acting antivirals
Presentation
-
YAZDANPANAH Yazdan
France
-
The long term impact of treatment on the outcome of liver disease?
Presentation
-
-
Interféron ou analogue ? (French speaking luncheon) (chairman)
Presentation
-
ZEUZEM Stefan
Germany
-
The long term impact of treatment on the outcome of liver disease? (chairman)
-
New therapeutic strategies (chairman)
Presentation
-
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy? (chairman)
Presentation
-
ZOULIM Fabien
France
-
The control of HBV related liver disease (chairman)
Presentation
-
